Research on Oral Anticancer Agents in the Contexts of Utilization, Adherence, and Health Care Delivery

May 18, 2020
3:00PM – 4:00PM ET

View WebinarExternal Web Site Policy

Slides (PDF, 160 KB)

FAQs (PDF, 99 KB)

Purpose

The purpose of this Webinar is to inform potential applicants of the special interest of the National Cancer Institute (NCI) in promoting research on oral anticancer medication utilization, adherence, and health care delivery (NOT-CA-20-026External Web Site Policy).

There are currently more than 50 U.S. FDA-approved oral anticancer agents and it is expected that the rate of development, approval, and use of these medications will continue to increase. Achieving maximal benefit of oral anticancer agents requires that they are prescribed, administered and monitored properly. Accomplishing this goal necessitates tracking utilization, identifying factors that influence adherence, and enhancing care delivery systems to support appropriate and safe use of these agents by clinicians and patients. Research studies supported by this NOSI should advance actionable knowledge regarding utilization, adherence, and/or care delivery of oral anticancer agents.

Presenters

Kate Castro, R.N., M.S., A.O.C.N.
Program Director, Office of the Associate Director
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

Kelly K Filipski, Ph.D., M.P.H.
Program Director, Clinical and Translational Epidemiology Branch
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

Wendy Nelson, Ph.D., M.P.H.
Program Director, Basic Biobehavioral and Psychological Sciences Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

Intended Audience

Extramural investigators at junior, mid, and senior levels.

This webinar is archived on the HDRP Events webpage.

Last Updated: 04 Jun, 2020